<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611584</url>
  </required_header>
  <id_info>
    <org_study_id>D1046</org_study_id>
    <nct_id>NCT01611584</nct_id>
  </id_info>
  <brief_title>A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to measure ALA-induced fluorescence in both normal and malignant
      tissue.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI left institution
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALA-induced fluorescence- lung cancer</measure>
    <time_frame>Participants will be followed for duration of the hospital stay, and up to 3 weeks after</time_frame>
    <description>Determine the relationship between ALA induced protoporphyrin IX (PplX) flourescence and histology in both normal and malignant tumors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine Feasibility of fluorescence</measure>
    <time_frame>Participants will be followed for the duration of their hospital study and up to 3 weeks after</time_frame>
    <description>Determine feasibility of integrating fluorescence detection into surgical pratice of resection for lung cancer.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Lung Cancer in Normal and Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>ALA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No arms for the trial. Participants will have proven or presumed lung cancer and will be assessed for participant by a research team member.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALA-induced Fluorescence</intervention_name>
    <description>ALA Dose- 20 mg/kg</description>
    <arm_group_label>ALA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion Criteria Patients (12 total patients with lung cancer) meeting eligibility
             criteria will be enrolled.

          -  Preoperative diagnosis of either presumed or documented non-small cell lung cancer.

          -  Tumor judged to be suitable for surgical resection based on preoperative evaluation of
             radiographic studies, pulmonary function tests, performance status and clinical
             judgment of surgeons at DHMC (Erkmen, Nugent)

          -  Age â‰¥ 18 years old.

          -  Population representative of our usual referral pattern including minority
             populations, women and those who are financially disadvantaged.

          -  Subjects capable of giving informed consent

        Exclusion Criteria:

          -  Pregnant Women

          -  Women who are breast feeding

          -  History of cutaneous photosensitivity

          -  Porphyria, hypersensitivity to porphyrins, photodermatosis

          -  Exfoliative dermatitis

          -  History of liver disease within the last 12 months

          -  Inability to comply with photosensitivity precautions associated with the study

          -  Inability to give informed consent

          -  AST, ALT, ALP or bilirubin levels greater than 2.5 times the normal limit at any time
             during the past 2 months

          -  Plasma creatinine in excess of 180 umol/L

          -  Women who are breast feeding

          -  History of cutaneous photosensitivity

          -  Porphyria, hypersensitivity to porphyrins, photodermatosis

          -  Exfoliative dermatitis

          -  History of liver disease within the last 12 months

          -  Inability to comply with photosensitivity precautions associated with the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cherie P Erkmen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <last_update_submitted>November 11, 2014</last_update_submitted>
  <last_update_submitted_qc>November 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALA</keyword>
  <keyword>Florescence</keyword>
  <keyword>Lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

